Natalie Staplin

16.5k total citations · 1 hit paper
57 papers, 1.4k citations indexed

About

Natalie Staplin is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Natalie Staplin has authored 57 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Nephrology, 20 papers in Cardiology and Cardiovascular Medicine and 18 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Natalie Staplin's work include Chronic Kidney Disease and Diabetes (16 papers), Blood Pressure and Hypertension Studies (14 papers) and Dialysis and Renal Disease Management (12 papers). Natalie Staplin is often cited by papers focused on Chronic Kidney Disease and Diabetes (16 papers), Blood Pressure and Hypertension Studies (14 papers) and Dialysis and Renal Disease Management (12 papers). Natalie Staplin collaborates with scholars based in United Kingdom, United States and Australia. Natalie Staplin's co-authors include Colin Baigent, William G. Herrington, Richard Haynes, Martin Landray, Jonathan Emberson, Parminder K. Judge, Alan Cass, Alejandro de la Sierra, Alastair Gray and Iryna Schlackow and has published in prestigious journals such as The Lancet, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Natalie Staplin

51 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients

2023 139 citations Natalie Staplin, Alejandro de la Sierra et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Natalie Staplin United Kingdom	20	460	460	417	258	248	57	1.4k
Anita Lloyd Canada	16	627 1.4×	375 0.8×	266 0.6×	314 1.2×	191 0.8×	37	1.4k
Per Ivarsen Denmark	24	676 1.5×	366 0.8×	324 0.8×	255 1.0×	309 1.2×	87	1.8k
Lori D. Bash United States	22	740 1.6×	911 2.0×	337 0.8×	486 1.9×	197 0.8×	54	2.2k
Fernando de Álvaro Spain	20	873 1.9×	501 1.1×	383 0.9×	306 1.2×	209 0.8×	57	1.7k
Adrian Liew Singapore	15	676 1.5×	177 0.4×	461 1.1×	215 0.8×	155 0.6×	61	1.3k
David C. Wheeler United Kingdom	18	730 1.6×	299 0.7×	234 0.6×	263 1.0×	178 0.7×	40	1.5k
Teresa K. Chen United States	15	747 1.6×	271 0.6×	209 0.5×	171 0.7×	220 0.9×	39	1.6k
Marit D. Solbu Norway	28	1.3k 2.9×	545 1.2×	367 0.9×	273 1.1×	209 0.8×	67	2.1k
Lucía Cea Soriano Spain	24	555 1.2×	463 1.0×	550 1.3×	628 2.4×	219 0.9×	88	2.2k
Solfrid Romundstad Norway	15	885 1.9×	539 1.2×	200 0.5×	123 0.5×	208 0.8×	33	1.5k

Countries citing papers authored by Natalie Staplin

Since Specialization

Citations

This map shows the geographic impact of Natalie Staplin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natalie Staplin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natalie Staplin more than expected).

Fields of papers citing papers by Natalie Staplin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natalie Staplin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natalie Staplin. The network helps show where Natalie Staplin may publish in the future.

Co-authorship network of co-authors of Natalie Staplin

This figure shows the co-authorship network connecting the top 25 collaborators of Natalie Staplin. A scholar is included among the top collaborators of Natalie Staplin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natalie Staplin. Natalie Staplin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Donovan, Killian, Jason Torres, Doreen Zhu, William G. Herrington, & Natalie Staplin. (2025). An application of the MR-Horse method to reduce selection bias in genome-wide association studies of disease progression. European Journal of Human Genetics. 33(12). 1677–1683.

Williams, Claire, Natalie Staplin, Parminder K. Judge, et al.. (2025). Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial. EClinicalMedicine. 85. 103338–103338. 1 indexed citations

Böhm, Michael, Alejandro de la Sierra, Felix Mahfoud, et al.. (2024). Office measurement vs. ambulatory blood pressure monitoring: associations with mortality in patients with or without diabetes. European Heart Journal. 45(31). 2851–2861. 3 indexed citations

Sierra, Alejandro de la, Luís M. Ruilope, Natalie Staplin, George S. Stergiou, & Bryan Williams. (2024). Mortality risks in different subtypes of masked hypertension in the Spanish ambulatory blood pressure monitoring registry. Journal of Hypertension. 43(4). 642–648. 3 indexed citations

Sierra, Alejandro de la, Luís M. Ruilope, Natalie Staplin, et al.. (2024). Resistant Hypertension and Mortality: An Observational Cohort Study. Hypertension. 81(11). 2350–2356. 7 indexed citations

Guimarães, Pedro, Andreas Keller, Michael Böhm, et al.. (2024). Artificial Intelligence–Derived Risk Prediction: A Novel Risk Calculator Using Office and Ambulatory Blood Pressure. Hypertension. 82(1). 46–56.

Mayne, Kaitlin J., Rebecca J. Sardell, Natalie Staplin, et al.. (2024). Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrology Dialysis Transplantation. 40(4). 720–730. 10 indexed citations

Wijesurendra, Rohan S., Rebecca J. Sardell, Raja Jayaram, et al.. (2023). Mechanisms of rosuvastatin-related acute kidney injury following cardiac surgery: the STICS trial. European Heart Journal. 45(8). 629–631. 4 indexed citations

Herrington, William G., Charlie Harper, Natalie Staplin, et al.. (2023). Impact of Outcome Adjudication in Kidney Disease Trials: Observations From the Study of Heart and Renal Protection. Kidney International Reports. 8(8). 1489–1495. 1 indexed citations

10.

Chapman, Daniel S., Parminder K. Judge, Rebecca J. Sardell, et al.. (2023). Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors. Kidney International. 103(4). 787–790. 1 indexed citations

11.

Staplin, Natalie, William G. Herrington, Federico Murgia, et al.. (2022). Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology. Hypertension. 79(12). 2671–2681. 14 indexed citations

12.

Donovan, Killian, William G. Herrington, Guillaume Paré, et al.. (2022). Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases. Clinical Journal of the American Society of Nephrology. 18(1). 17–27. 9 indexed citations

13.

Alegre-Díaz, Jesús, William G. Herrington, Natalie Staplin, et al.. (2021). Association of Kidney Function With NMR-Quantified Lipids, Lipoproteins, and Metabolic Measures in Mexican Adults. The Journal of Clinical Endocrinology & Metabolism. 106(10). 2828–2839. 9 indexed citations

14.

Storey, Benjamin C., Natalie Staplin, Charlie Harper, et al.. (2018). Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy. Kidney International. 93(5). 1165–1174. 21 indexed citations

15.

Haynes, Richard, Lisa Blackwell, Natalie Staplin, et al.. (2017). Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial. American Journal of Transplantation. 18(6). 1424–1434. 18 indexed citations

16.

Reith, Christina, Natalie Staplin, William G. Herrington, et al.. (2017). Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrology. 18(1). 147–147. 10 indexed citations

17.

Mafham, Marion, Natalie Staplin, Jonathan Emberson, et al.. (2016). Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation. 33(2). 257–264. 8 indexed citations

18.

Herrington, William G., Jonathan Emberson, Natalie Staplin, et al.. (2014). The Effect of Lowering LDL Cholesterol on Vascular Access Patency. Clinical Journal of the American Society of Nephrology. 9(5). 914–919. 18 indexed citations

19.

Haynes, Richard, Natalie Staplin, Jonathan Emberson, et al.. (2014). Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases. 64(1). 40–48. 55 indexed citations

20.

Staplin, Natalie, Jonathan Emberson, Colin Baigent, et al.. (2014). CANCER AND CHRONIC KIDNEY DISEASE: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF 33,618 PARTICIPANTS. Oxford University Research Archive (ORA) (University of Oxford). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact